EUR 13.54 For Business Accounts Only

TSUMURA & COMPANY suffers a double requalification, which weighs heavily on its rating, now at Neutral.

The independent financial analyst theScreener just downgraded the general evaluation of TSUMURA & COMPANY (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title loses a star(s) and now shows 1 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as moderately risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Neutral. As of the analysis date May 10, 2019, the closing price was JPY 3,025.00 and its target price was estimated at JPY 2,873.75.
Tsumura & Co.

Tsumura is a pharmaceutical company primarily engaged in the manufacture and sale of ethical pharmaceutical and over-the counter drugs. Co.'s principal products include Kampo (Japanese traditional herbal medicines), such as "Daikenchuto," "Hochuekkito," "Saireito," "Kamishoyosan," "Goshajinkigan," "Bakumondoto," "Shakuyakukanzoto," "Shoseiryuto," "Kakkonto" and others; as well as bath additives , such as "Bath Herb." In addition, Co., through its subsidiaries, is engaged in the operation of pharmacies, the provision of transportation services and the development of medicine in the U.S.


Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded


Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch